Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0011—Cancer antigens
  • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
  • A61K39/001116—Receptors for cytokines
  • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/10—Cellular immunotherapy characterised by the cell type used
  • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
  • A61K40/31—Chimeric antigen receptors [CAR]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K40/00—Cellular immunotherapy
  • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
  • A61K40/41—Vertebrate antigens
  • A61K40/42—Cancer antigens
  • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
  • A61K40/4214—Receptors for cytokines
  • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/80—Vaccine for a specifically defined cancer
  • A61K2039/804—Blood cells [leukemia, lymphoma]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
  • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
  • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present disclosure provides methods of treating cancer (e.g ., multiple myeloma) or light chain amyloidosis in a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the subject.
• a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the subject.
• BCMA B-cell maturation antigen
• B-cell maturation antigen is a substrate of gamma secretase (Laurent et al., Nat Commun. 2015 Jun 11, 6:7333).
• Gamma secretase is a multi-subunit protease complex that cleaves single-pass transmembrane proteins at residues within the transmembrane domain.
• BCMA expression has been linked to a number of cancers, including hematological cancers, such as multiple myeloma.
• the present disclosure relates to a method of treating cancer in a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a BCMA-directed therapy to the subject.
• the present disclosure relates to the use of a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a BCMA-directed therapy in treating cancer in a subject in need thereof.
• the cancer is characterized by inadequate expression of BCMA.
• the cancer is characterized by detectable soluble BCMA levels in a serum sample from the subject.
• the cancer is a hematologic cancer.
• the hematologic cancer is multiple myeloma.
• the cancer is selected from a group consisting of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and myelogenous leukemia (ML).
• the present disclosure relates to a method of treating light chain amyloidosis comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a BCMA-directed therapy to a subject in need thereof.
• the present disclosure relates to the use of a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a BCMA-directed therapy in treating light chain amyloidosis in a subject in need thereof.
• the Form A of nirogacestat dihydrobromide reduces the shedding of
• BCMA from the surface of a BCMA positive cell in the subject.
• the Form A of nirogacestat dihydrobromide reduces the levels of soluble BCMA in the subject.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive cancer cells in the subject.
• Form A of nirogacestat dihydrobromide increases the
• BCMA density of membrane bound BCMA on the surface of BCMA-positive cancer cells in the subject is the BCMA density of membrane bound BCMA on the surface of BCMA-positive cancer cells in the subject.
• Form A of nirogacestat dihydrobromide enhances the activity of BCMA-directed therapy in the subject.
• the Form A of nirogacestat dihydrobromide enables administration of a lower dose of BCMA-directed therapy to the subject as compared with the amount of the BCMA-directed therapy administered alone while maintaining equal levels of efficacy (e.g ., one or more of the treatment endpoints discussed below e.g ., CR, nCR, sCR, MRD)).
• the Form A of nirogacestat dihydrobromide enables administration of a lower dose or the same dose of BCMA- directed therapy to the subject as compared with the amount of the BCMA-directed therapy administered alone while achieving increased levels of efficacy (e.g., one or more of the treatment endpoints discussed below (e.g, CR, nCR, sCR, MRD)).
• the subject is administered the Form A of nirogacestat dihydrobromide at a dose from about 20 mg to about 220 mg.
• the subject is administered the Form A of nirogacestat dihydrobromide at a dose from about 20 mg to about 220 mg once or twice daily.
• the subject is administered the Form A of nirogacestat dihydrobromide at a dose from about 20 mg to about 220 mg once or twice daily for at least one week.
• the Form A of nirogacestat dihydrobromide is administered to the subject before, concomitantly, or subsequently to the administering of the BCMA- directed therapy to the subject.
• the subject is administered the combination therapy as a first line of therapy.
• the subject with cancer or light chain amyloidosis being treated with
• Form A of nirogacestat dihydrobromide and a BCMA-directed therapy has been previously treated for the cancer or light chain amyloidosis.
• the subject with cancer or light chain amyloidosis being treated with Form A of nirogacestat dihydrobromide and a BCMA-directed therapy has been previously treated for the cancer or light chain amyloidosis with one or more of a proteasome inhibitor, an immunomodulatory therapy, an immunotherapy (e.g ., a monoclonal antibody, such as a monoclonal antibody directed to CD38), a stem cell transplant, a chemotherapy, a targeted therapy (e.g., an XPOl inhibitor), or a BCMA-directed therapy not in combination with nirogacestat.
• a proteasome inhibitor e.g a proteasome inhibitor
• an immunomodulatory therapy e.g a monoclonal antibody, such as a monoclonal antibody directed to CD38
• a stem cell transplant e.g
• the Form A of nirogacestat dihydrobromide is administered orally and the BCMA-directed therapy is administered intravenously or subcutaneously to the subject.
• the BCMA-directed therapy includes one or more of an allogeneic chimeric antigen receptor T cell therapy, an autologous chimeric antigen receptor T cell therapy, an immunotherapy (e.g, a monoclonal antibody therapy), an antibody drug conjugate therapy, or a bispecific antibody therapy with dual specificity for BCMA and an immune-related target (e.g, CD3).
• the BCMA-directed therapy includes at least an allogeneic chimeric antigen receptor T cell therapy.
• the BCMA-directed therapy includes at least an autologous chimeric antigen receptor T cell therapy.
• the BCMA-directed therapy includes at least an immunotherapy (e.g, a monoclonal antibody therapy).
• the BCMA- directed therapy includes at least an antibody drug conjugate therapy.
• the BCMA-directed therapy includes at least a bispecific antibody therapy with dual specificity for BCMA and an immune-related target (e.g ., CD3).
• the Form A of nirogacestat dihydrobromide is administered in a tablet form.
• the subject is human.
• Figure l is a powder X-ray diffraction pattern ("XRPD") corresponding to crystalline Form A.
• Figure 2 is a thermogravimetric analysis thermogram (“TGA”) corresponding to crystalline Form A.
• Figure 3 is a differential scanning calorimetry thermogram (“DSC") corresponding to crystalline Form A.
• BCMA B-cell maturation antigen
• sBCMA soluble BCMA
• BCMA shedding can create challenges for therapeutic agents that target BCMA. Some of the challenges include the following. First, BCMA shedding can decrease surface BCMA expression on cancer cells which then reduces target binding sites for BCMA-targeting therapeutic agents. Second, BCMA shedding can generate a soluble BCMA sink that binds to BCMA-targeting therapeutic agents and diverts these agents from binding to membrane bound BCMA expressed on cancer cells.
• soluble BCMA molecules can also sequester circulating BCMA ligands, e.g ., B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), and prevent them from stimulating BCMA expressed on the surface of B cells and plasma cells, thereby leading to deficient humoral immune responses in patients.
• BCMA ligands e.g ., B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL)
• the use of gamma secretase inhibitors to prevent BCMA shedding can increase the effectiveness of BCMA-directed therapies that target pathological B cells expressing BCMA.
• the present disclosure provides a method of treating cancer or light chain amyloidosis in a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a BCMA- directed therapy to the subject.
• the cancer is characterized by inadequate expression of BCMA.
• the cancer is characterized by detectable sBCMA levels.
• the cancer is a hematologic cancer.
• the hematologic cancer is multiple myeloma.
• the cancer is selected from a group consisting of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and myelogenous leukemia (ML).
• CLL chronic lymphocytic leukemia
• DLBCL diffuse large B cell lymphoma
• FL follicular lymphoma
• BL Burkitt lymphoma
• MCL mantle cell lymphoma
• ML myelogenous leukemia
• the present disclosure provides a method of treating light chain amyloidosis a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a BCMA- directed therapy to the subject.
• subject refers to an animal, including, but not limited to, a primate
• subject e.g ., human
• cow sheep, goat, horse, dog, cat, rabbit, rat, or mouse.
• patient are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject.
• a subject is successfully "treated” for cancer, e.g., multiple myeloma, according to the methods of the present invention if the patient shows one or more of the following: a reduction in the number of or complete absence of cancer cells; relief of one or more symptoms associated with the specific cancer; reduced morbidity and mortality; improvement in quality of life; increased progression-free survival (PFS), disease-free survival (DFS), overall survival (OS), metastasis-free survival (MFS), complete response (CR), near complete response (nCR), stringent complete response (sCR), minor response (MR), minimal residual disease (MRD), partial response (PR), very good partial response (VGPR), stable disease (SD), a decrease in progressive disease (PD), an increased time to progression (TTP), or any combination thereof.
• PFS progression-free survival
• DFS disease-free survival
• OS overall survival
• MFS metastasis-free survival
• complete response CR
• nCR near complete response
• sCR stringent complete response
• MR minimal residual disease
• the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma criteria can be used to determine whether the combination of an effective amount of Form A of nirogacestat dihydrobromide and the BCMA-directed therapy meets any of these particular endpoints (e.g, CR, nCR, sCR, MRD).
• CR for a subject having multiple myeloma can be a negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ⁇ 5% plasma cells in bone marrow.
• sCR for a subject having multiple myeloma can be a CR plus normal serum free light chain (FLC) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunoflorence.
• FLC normal serum free light chain
• VGPR for a subject having multiple myeloma can be a serum and urine M-protein detectable by immunofixation but not on electrophoresis or > 90% reduction in serum M- protein plus urine M-protein level ⁇ 100 mg/24 h.
• PD for a subject having multiple myeloma can be an increase of > 25% from lowest response value in any one or more of the following:
• bone marrow plasma cell percentage (the absolute percentage must be > 10%);
• PR for a subject having multiple myeloma can be a > 50% reduction of serum M- protein and reduction in 24 hours urinary M-protein by > 90% or to ⁇ 200 mg/24 h. If the serum and urine M-protein are unmeasurable, a > 50% decrease in the difference between involved and uninvolved FLC levels can be required in place of the M-protein criteria. If the serum and urine M-protein are not measurable, and the serum free light assay can also not be measured, > 50% reduction in plasma cells can be required in place of the M-protein, provided a baseline bone marrow plasma cell percentage was > 30%. In addition, if present at baseline, a > 50% reduction in the size of soft tissue plasmacytomas can also be required.
• SD for a subject having multiple myeloma can be not meeting criteria for CR
• a subject having multiple myeloma that tests MRD negative has less than one myeloma cell per million bone marrow cells.
• parenteral administration refers to delivering one or more compounds or compositions to a subject parenterally, enterally, or topically.
• parenteral administration include, but are not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticulare, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
• enteral administration include, but are not limited to oral, inhalation, intranasal, sublingual, and rectal administration.
• topical administration include, but are not limited to, transdermal and vaginal administration.
• the term "effective amount” refers to an amount of a compound, formulation, material, or composition, as described herein effective to achieve a particular biological result.
• terapéuticaally effective amount includes the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of a disorder, disease, or condition being treated.
• therapeutically effective amount also refers to the amount of a compound that is sufficient to elicit the biological or medical response of a cell, tissue, system, animal, or human, which is being sought by a researcher, veterinarian, medical doctor, or clinician.
• pharmaceutically acceptable carrier refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material.
• each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio.
• a gamma secretase inhibitor e.g ., nirogacestat dihydrobromide
• first line of therapy refers to a treatment regimen generally accepted or recommended by the medical establishment or a regulatory authority, e.g. , the U.S. Food and Drug Administration or the European Medicines Agency, for the initial treatment of cancer or light chain amyloidosis in a subject.
• the subject having cancer or light chain amyloidosis can have previously received and/or be currently being treated for one or more unrelated diseases or disorders (e.g, anxiety).
• the present disclosure relates combination therapies comprising Form A of nirogacestat dihydrobromide (a dihydrobromide salt of (S)-2-(((S)-6,8-difluoro-l,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(l-(2-methyl-l-(neopentylamino)propan-2-yl)-lH- imidazol-4-yl)pentanamide of Formula (I))
• Form A of nirogacestat dihydrobromide is characterized by an XRPD pattern having peaks at 8.8 ⁇ 0.2, 9.8 ⁇ 0.2, and 23.3 ⁇ 0.2 degrees two theta.
• crystalline Form A of nirogacestat dihydrobromide is anhydrous.
• the melting point of crystalline Form A of nirogacestat dihydrobromide is about 254 °C.
• Form A of nirogacestat dihydrobromide is characterized by an
• Form A of nirogacestat dihydrobromide is characterized by an XRPD pattern having peaks at 8.8 ⁇ 0.2, 9.8 ⁇ 0.2, 23.3 ⁇ 0.2, 25.4 ⁇ 0.2, 28.0 ⁇ 0.2, and 29.3 ⁇ 0.2 degrees two theta when measured by Cu Ka radiation.
• Form A of nirogacestat dihydrobromide is characterized by an XRPD pattern having peaks at 8.8 ⁇ 0.2, 9.8 ⁇ 0.2, 20.0 ⁇ 0.2, 23.3 ⁇ 0.2, 25.4 ⁇ 0.2, 28.0 ⁇ 0.2, 29.3 ⁇ 0.2, and 32.5 ⁇ 0.2 degrees two theta when measured by Cu Ka radiation.
• Form A of nirogacestat dihydrobromide is characterized by an
• Form A of nirogacestat dihydrobromide is characterized by a TGA profile substantially as shown in Figure 2.
• Form A is characterized by a DSC profile substantially as shown in Figure 3.
• Form A of nirogacestat dihydrobromide can be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g, through the use of a patch) routes.
• the Form A of nirogacestat dihydrobromide can be administered to subjects via the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal, topical or transdermal (e.g, through the use of a patch) routes.
• the Form A of nirogacestat dihydrobromide is orally administered.
• the Form A of nirogacestat dihydrobromide is provided in tablet form.
• the pharmaceutical composition comprises Form A of nirogacestat dihydrobromide.
• the pharmaceutical composition is an oral tablet comprising Form A of nirogacestat dihydrobromide and a pharmaceutically acceptable carrier.
• the tablet comprises about 10 mg to about 400 mg of Form A of nirogacestat dihydrobromide.
• the tablet comprises about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg of Form A of nirogacestat dihydrobromide.
• the tablet comprises about 10 mg of Form A of nirogacestat dihydrobromide. In one aspect, the tablet comprises about 20 mg of Form A of nirogacestat dihydrobromide. In one aspect, the tablet comprises about 50 mg of Form A of nirogacestat dihydrobromide. In one aspect, the tablet comprises about 100 mg of Form A of nirogacestat dihydrobromide. In one aspect, the tablet comprises about 150 mg of Form A of nirogacestat dihydrobromide. In one aspect, the tablet comprises about 200 mg of Form A of nirogacestat dihydrobromide. In one aspect, the tablet comprises about 220 mg of Form A of nirogacestat dihydrobromide.
• microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine can be employed along with various disintegrants such as starch (preferably com, potato or tapioca starch), methylcellulose, alginic acid and certain complex silicates, together with granulation binders such as polyvinylpyrrolidone, sucrose, gelatin and acacia, can be included in a tablet.
• disintegrants such as starch (preferably com, potato or tapioca starch), methylcellulose, alginic acid and certain complex silicates, together with granulation binders such as polyvinylpyrrolidone, sucrose, gelatin and acacia, can be included in a tablet.
• lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
• Solid compositions of a similar type can also be employed as fillers in gelatin capsules.
• Preferred materials in this connection include lactose or milk sugar as well as high molecular weight polyethylene glycols.
• the active ingredient can be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
• solutions containing nirogacestat can be prepared in either sesame or peanut oil, in aqueous propylene glycol, or in sterile water or saline.
• the aqueous solutions should be suitably buffered (preferably pH greater than 8) if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
• These aqueous solutions are suitable for intravenous injection purposes.
• the oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.
• BCMA B-cell maturation antigen
• the BCMA-directed therapy includes but is not limited to, one or more of an allogeneic chimeric antigen receptor T cell therapy, an autologous chimeric antigen receptor T cell therapy, an immunotherapy (e.g ., a monoclonal antibody therapy), an antibody drug conjugate therapy, or a bispecific antibody therapy with dual specificity for BCMA and an immune-related target (e.g., CD3).
• the BCMA- directed therapy can include at least an allogeneic chimeric antigen receptor T cell therapy.
• the BCMA-directed therapy can include at least an autologous chimeric antigen receptor T cell therapy.
• the BCMA-directed therapy can include at least an immunotherapy (e.g, a monoclonal antibody therapy). In some aspects, the BCMA-directed therapy can include at least an antibody drug conjugate. In some aspects, the BCMA-directed therapy can include at least a bispecific antibody therapy with dual specificity for BCMA and an immune-related target (CD3). In some aspects the BCMA-directed therapy includes any combination of the therapies listed above.
• an immunotherapy e.g, a monoclonal antibody therapy
• the BCMA-directed therapy can include at least an antibody drug conjugate.
• the BCMA-directed therapy can include at least a bispecific antibody therapy with dual specificity for BCMA and an immune-related target (CD3). In some aspects the BCMA-directed therapy includes any combination of the therapies listed above.
• the BCMA-directed therapy can be formulated for intravenous or subcutaneous administration in a liquid dosage form.
• the combination of an effective amount of Form A of nirogacestat dihydrobromide and BCMA-directed therapy is administered to treat cancer in a subject.
• the cancer is a hematologic cancer.
• the hematologic cancer is multiple myeloma.
• the cancer is selected from a group consisting of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and myelogenous leukemia (ML).
• the subject with cancer exhibits a complete response following administration of the effective amount of Form A of nirogacestat dihydrobromide and BCMA-directed therapy.
• the subject with cancer e.g., multiple myeloma
• the subject with cancer e.g., multiple myeloma
• the subject with cancer exhibits a minor response following administration of the effective amount of Form A of nirogacestat dihydrobromide and BCMA-directed therapy.
• the subject with cancer e.g, multiple myeloma
• the subject with cancer e.g, multiple myeloma
• the subject with cancer e.g, multiple myeloma
• the combination of an effective amount of Form A of nirogacestat dihydrobromide and BCMA-directed therapy is administered to treat light chain amyloidosis in a subject.
• the Form A of nirogacestat dihydrobromide is administered to the subject with cancer (e.g, multiple myeloma) or light chain amyloidosis before, concomitantly, or subsequently to the administering of the BCMA-directed therapy to the subject.
• cancer e.g, multiple myeloma
• light chain amyloidosis e.g, multiple myeloma
• the subject with cancer e.g. multiple myeloma
• light chain amyloidosis is administered the combination therapy as the first line of therapy.
• the subject having cancer e.g., multiple myeloma
• light chain amyloidosis can have previously received and/or be currently being treated for one or more unrelated diseases or disorders (e.g., anxiety).
• combination of an effective amount of Form A of nirogacestat and the BCMA-directed therapy can be used in a combination with one or more of other known cancer treatments.
• the other known cancer treatments include but are not limited to, a radiation therapy, a chemotherapy, a stem cell transplant an immunotherapy (e.g ., a monoclonal antibody, such as a monoclonal antibody directed to CD38), a proteasome inhibitor, an immunomodulatory therapy, a hormone therapy, a photodynamic therapy, a targeted therapy (e.g., an XPOl inhibitor), or a combination thereof.
• the other known cancer treatments can be an immunomodulatory therapy, a proteasome inhibitor, an immunotherapy (e.g., a monoclonal antibody, such as a monoclonal antibody directed to CD38), or a combination thereof.
• the other known cancer treatment can be a combination of an immunomodulatory therapy, a proteasome inhibitor, and an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38).
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis.
• the subject with cancer (e.g, multiple myeloma) or light chain amyloidosis being treated with Form A of nirogacestat dihydrobromide and a BCMA-directed therapy has been previously treated for the cancer or light chain amyloidosis with one or more of a proteasome inhibitor, an immunomodulatory therapy, an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), a stem cell transplant, a chemotherapy, a targeted therapy (e.g, an XPOl inhibitor), a BCMA- directed therapy not in combination with nirogacestat to the subject, or combinations thereof.
• a proteasome inhibitor e.g, an immunomodulatory therapy, an immunotherapy (e.g, a monoclonal antibody, such as a monoclon
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of a proteasome inhibitor to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of an immunomodulatory therapy to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38) to the subject.
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of a chemotherapy to the subject.
• the subject has cancer (e.g ., multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of a targeted therapy (e.g., an XPOl inhibitor) to the subject.
• a targeted therapy e.g., an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of a BCMA- directed therapy not in combination with nirogacestat to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor and an immunomodulatory therapy to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor and an immunotherapy (e.g., a monoclonal antibody, such as a monoclonal antibody directed to CD38) to the subject.
• an immunotherapy e.g., a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of a proteasome inhibitor to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor and a chemotherapy to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor and a targeted therapy (e.g, an XPOl inhibitor) to the subject.
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunomodulatory therapy and an immunotherapy (e.g ., a monoclonal antibody, such as a monoclonal antibody directed to CD38) to the subject.
• an immunomodulatory therapy and an immunotherapy e.g ., a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g., multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of an immunomodulatory therapy to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunomodulatory therapy and a chemotherapy to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunomodulatory therapy and a targeted therapy (e.g, an XPOl inhibitor) to the subject.
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunomodulatory therapy and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38) to the subject.
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38) and a chemotherapy to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38) and a targeted therapy (e.g, an XPOl inhibitor) to the subject.
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38) and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• a BCMA-directed therapy not in combination with nirogacestat to the subject.
• the subject has cancer (e.g ., multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of a chemotherapy to the subject.
• the subject has cancer (e.g., multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of a targeted therapy (e.g, an XPOl inhibitor) to the subject.
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of a BCMA-directed therapy not in combination with nirogacestat to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a chemotherapy and a targeted therapy (e.g, an XPOl inhibitor) to the subject.
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a chemotherapy and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a targeted therapy (e.g, an XPOl inhibitor) and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor, an immunomodulatory therapy, and an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38) to the subject.
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of the combination of a proteasome inhibitor and an immunomodulatory therapy to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor, an immunomodulatory therapy, and a chemotherapy to the subject.
• the subject has cancer (e.g ., multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor, an immunomodulatory therapy, and a targeted therapy (e.g., an XPOl inhibitor) to the subject.
• a targeted therapy e.g., an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor, an immunomodulatory therapy, and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of the combination of a proteasome inhibitor and an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38).
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor, an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), and a chemotherapy to the subject.
• a proteasome inhibitor e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor, an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), and a targeted therapy (e.g, an XPOl inhibitor) to the subject.
• a proteasome inhibitor e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor, an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• a proteasome inhibitor e.g, an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• BCMA-directed therapy not in combination with nirogacestat
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of the combination of an immunomodulatory therapy and an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38) to the subject.
• cancer e.g, multiple myeloma
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g ., multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunomodulatory therapy, an immunotherapy (e.g., a monoclonal antibody, such as a monoclonal antibody directed to CD38), and a chemotherapy to the subject.
• an immunomodulatory therapy e.g., a monoclonal antibody, such as a monoclonal antibody directed to CD38
• a chemotherapy e.g., a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunomodulatory therapy, an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), and a targeted therapy (e.g, an XPOl inhibitor) to the subject.
• an immunomodulatory therapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunomodulatory therapy, an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• an immunomodulatory therapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• a BCMA-directed therapy not in combination with nirogacestat
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of the combination of an immunotherapy (e.g., a monoclonal antibody, such as a monoclonal antibody directed to CD38) and a BCMA- directed therapy not in combination with nirogacestat to the subject.
• an immunotherapy e.g., a monoclonal antibody, such as a monoclonal antibody directed to CD38
• BCMA- directed therapy not in combination with nirogacestat
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), a chemotherapy, and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of an immunotherapy (e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38), a targeted therapy (e.g, an XPOl inhibitor), and a BCMA- directed therapy not in combination with nirogacestat to the subject.
• an immunotherapy e.g, a monoclonal antibody, such as a monoclonal antibody directed to CD38
• a targeted therapy e.g, an XPOl inhibitor
• BCMA- directed therapy not in combination with nirogacestat
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of the combination of a chemotherapy and a targeted therapy (e.g ., an XPOl inhibitor) to the subject.
• a targeted therapy e.g ., an XPOl inhibitor
• the subject has cancer (e.g., multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of the combination of a chemotherapy and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising a stem cell transplant and administration of the combination of a targeted therapy (e.g, an XPOl inhibitor) and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• a targeted therapy e.g, an XPOl inhibitor
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a chemotherapy, a targeted therapy (e.g, an XPOl inhibitor), and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• cancer e.g, multiple myeloma
• a targeted therapy e.g, an XPOl inhibitor
• BCMA-directed therapy not in combination with nirogacestat
• the subject has cancer (e.g, multiple myeloma) or light chain amyloidosis after being previously treated for the cancer or light chain amyloidosis by a method comprising administration of the combination of a proteasome inhibitor, an immunomodulatory therapy, an immunotherapy (e.g, a monoclonal antibody such as a monoclonal antibody directed to CD38), and a BCMA-directed therapy not in combination with nirogacestat to the subject.
• a proteasome inhibitor e.g, an immunomodulatory therapy
• an immunotherapy e.g, a monoclonal antibody such as a monoclonal antibody directed to CD38
• BCMA-directed therapy not in combination with nirogacestat
• the Form A of nirogacestat dihydrobromide prevents the cleavage of membrane bound BCMA, thereby reducing the shedding of BCMA from the surface of a BCMA positive cell in the subject.
• the Form A of nirogacestat dihydrobromide reduces about 5% to about 100% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces about 10% to about 100% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces about 15% to about 95% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 20% to about 90% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 25% to about 85% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces about 30% to about 80% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 35% to about 75% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 40% to about 70% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces about 45% to about 65% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 50% to about 60% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 50% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat dihydrobromide.
• the Form A of nirogacestat dihydrobromide reduces about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% shedding of BCMA from the surface of a BCMA positive cell in the subject as compared to no administration of Form A of nirogacestat dihydrobromide.
• the Form A of nirogacestat dihydrobromide prevents the cleavage of membrane bound BCMA, thereby reducing the levels of sBCMA in the subject.
• the Form A of nirogacestat dihydrobromide reduces about 5% to about 100% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 10% to about 100% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 15% to about 95% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces about 20% to about 90% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 25% to about 85% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 30% to about 80% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces about 35% to about 75% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 40% to about 70% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 45% to about 65% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces about 50% to about 60% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat. In some aspects, the Form A of nirogacestat dihydrobromide reduces about 50% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat.
• the Form A of nirogacestat dihydrobromide reduces about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% of the levels of sBCMA in the subject as compared to no administration of Form A of nirogacestat.
• the soluble B-cell maturation antigen (sBCMA) is measured from cell supernatants using an immunoassay (e.g ., ELISA), HPLC-MS or MS.
• an immunoassay e.g ., ELISA
• HPLC-MS e.g., HPLC-MS
• MS e.g., MS
• serum and supernatant samples from the subject can be analyzed by
• BCMA enzyme-linked immunosorbent assay to determine the levels of soluble BCMA in the subject.
• serum or supernatant samples can be diluted or concentrated and the BCMA ELISA assay can be carried out according to the manufacturer's protocol.
• the ELISA plates can be analyzed using a plate reader.
• the serum and supernatant samples from the subject can be analyzed by high-performance liquid chromatography coupled to a mass spectrometer (HPLC-MS) to determine the levels of soluble BCMA in the subject.
• HPLC-MS mass spectrometer
• the serum and supernatant samples from the subject can be analyzed by a mass spectrometer (MS) to determine the levels of soluble BCMA in the subject.
• the subject administered Form A of nirogacestat dihydrobromide exhibits a greater number of BCMA-positive multiple myeloma cells after administration (post-administration) as compared with the number of BCMA- positive multiple myeloma cells prior to administration (baseline), i.e., a greater percentage of BCMA-positive multiple myeloma cells post-administration as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 5% to about 99% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 10% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 20% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 10% to about 99% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 25% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 30% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 35% to about 99% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 40% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 45% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 50% to about 99% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 60% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 10% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 65% to about 99% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 70% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 75% to about 99% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 80% to about 99% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post- administration about 10% to about 90% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 20% to about 90% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 30% to about 90% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 40% to about 90% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 50% to about 90% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 60% to about 90% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 70% to about 90% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 10% to about 80% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 20% to about 80% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 30% to about 80% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 40% to about 80% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 50% to about 80% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 60% to about 80% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 10% to about 70% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 20% to about 70% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 30% to about 70% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 40% to about 70% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 50% to about 70% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 10% to about 60% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 20% to about 60% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 30% to about 60% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 40% to about 60% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 10% to about 50% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 20% to about 50% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 30% to about 50% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 10% to about 40% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 20% to about 40% as compared with baseline.
• the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post administration about 10% to about 30% as compared with baseline. In some aspects, the Form A of nirogacestat dihydrobromide increases the percentage of BCMA-positive multiple myeloma cells post-administration about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 99%.
• the percentage of BCMA-positive multiple myeloma cells is measured by gating on negativity or positivity using flow cytometry.
• the multiple myeloma cells are extracted from the subject.
• the multiple myeloma cells are extracted from the subject through bone marrow aspiration.
• flow cytometry assessment of bone marrow aspirate material can be performed directly on aspirate without pretreatment or following a brief ammonium chloride red blood cell lysis step. See e.g., Pont, M., et al., Blood 134:1585-97 (2019).
• the premeasurement procedure can be adopted from established protocols next generation flow cytometric analysis for bone marrow using flow cytometer.
• the bone marrow aspirate can be diluted with appropriate solution and incubated under appropriate conditions.
• the cells can then be collected and washed with flow cytometry buffer (e.g, PBS with 1% fetal bovine serum), stained with Live/Dead viability dye.
• flow cytometry buffer e.g, PBS with 1% fetal bovine serum
• Surface staining can be done with a mixture of antibodies to one or more of the group selected from CD45, CD 19, CD138, CD38, CD14, CD56, CD20, CD3, CD269 (BCMA), or CD274 (PD-L1).
• Aliquots of normal donor PBMC cells can be stained in parallel as controls.
• the cells can then be washed before permeabilization/fixation using Cytofix/Cytoperm reagent for appropriate time at room temperature, washed, and stained with a mixture of antibodies to kappa and lambda immunoglobulin light chains.
• the samples can then be washed before resuspension in PBS and acquisition on a flow cytometer equipped with proper lasers. A minimum number of cells (e.g, 5 c 10 6 cells) can be acquired per sample. Results can be analyzed using software.
• the Form A of nirogacestat dihydrobromide increases density of membrane bound BCMA on the surface of BCMA-positive cancer cells.
• the Form A of nirogacestat dihydrobromide increases the density of membrane bound BCMA on the surface of BCMA-positive cancer cells in the subject 2-fold, 3-fold 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 11-fold, 12-fold, 13-fold, 14-fold, 15-fold, 16-fold, 17-fold, 18-fold, 19-fold, 20-fold, 21-fold, 22-fold, 23-fold, 24-fold, 25-fold, 50- fold, 75-fold, 100-fold, 125-fold, 150-fold, 175-fold, 200-fold, 225-fold, or 250-fold.
• surface expression of human BCMA can be determined using flow cytometry and appropriate secondary antibodies.
• the Form A of nirogacestat dihydrobromide can be administered to enhance the activity of BCMA-directed therapy in the subject.
• the activity of the combination of the effective amount of Form A of nirogacestat dihydrobromide and the BCMA-directed therapy is measured by cancer cell killing and/or immune-mediated cancer cell killing or clearance.
• the Form A of nirogacestat dihydrobromide enables administration of a lower dose of the BCMA-directed therapy to the subject as compared with the amount of the BCMA-directed therapy that would have been administered alone in order to achieve equal levels of efficacy (e.g ., one or more of the treatment endpoints discussed above (e.g., CR, nCR, sCR, MRD)).
• the Form A of nirogacestat dihydrobromide enables administration of a lower dose or the same dose of BCMA-directed therapy to the subject as compared with the amount of the BCMA- directed therapy administered alone while achieving increased levels of efficacy (e.g, one or more of the treatment endpoints discussed above (e.g, CR, nCR, sCR, MRD)).
• Form A of nirogacestat dihydrobromide is administered in doses ranging from about 0.1 mg to about 1000 mg daily. In one aspect, a subject is administered about 50 mg to about 500 mg of Form A of nirogacestat dihydrobromide daily. In another aspect, a subject is administered about 100 mg to about 400 mg of Form A of nirogacestat dihydrobromide daily. In another aspect, a subject is administered about 20 mg to about 220 mg of Form A of nirogacestat dihydrobromide daily.
• a subject is administered about 20 mg, about 25 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 220 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg daily of Form A of nirogacestat dihydrobromide.
• the total daily dose can be provided as single or divided doses (i.e., 1, 2, 3, or 4 doses per day). In one aspect, the total daily dose is provided as two doses.
• a 300 mg or 200 mg total daily dose can be administered to a subject as two separate 150 mg or 100 mg doses, respectively.
• three tablets comprising 50 mg of Form A of nirogacestat dihydrobromide twice daily or 200 mg daily dose can be administered to a subject as two tablets comprising 50 mg of Form A of nirogacestat dihydrobromide twice daily.
• the Form A of nirogacestat dihydrobromide is administered orally and the BCMA-directed therapy is administered intravenously or subcutaneously to the subject.
• the subject is human.
• Table 1 shows kinetic solubility of dihydrobromide salt of (s)- 2-(((s)-6,8-difluoro- 1,2,3, 4-tetrahydronaphthalen-2-yl)amino)-n-(l -(2-methyl- 1- (neopentylamino)propan-2-yl)-lh-imidazol-4-yl)pentanamide.
• Table 2 shows results of stable form and hydrate screen.
• Solids were suspended in specified solvents. The suspensions were then agitated at ambient or set temperature. After a given amount of time solids were isolated.
• Solutions of starting material were prepared in specified solvents at elevated temperature using a hot plate for heating. These were typically hot-filtered through a 0.2 pm nylon filter into warm receiving vials. The vials were either quickly transferred into a sub-ambient temperature bath (typically dry ice/acetone) for crash cooling (CC), removed from the hot place for fast cooling (FC) or the heat was turned off to allow for slow cooling (SC). If solids precipitated, they were isolated cold by vacuum filtration. If the solution remained clear, the sample was either kept at sub-ambient temperatures or further crystallization techniques were applied.
• CC crash cooling
• FC fast cooling
• SC slow cooling
• Solutions of starting material were allowed to partially evaporate or evaporate to dryness at ambient or elevated temperature from open vials for fast evaporation (FE) or from vials covered with aluminum foil with pin holes for slow evaporation (SE). Prior to evaporation, solutions were filtered at ambient or elevated temperature using 0.2 pm nylon filters.
• Solutions of starting material were prepared at ambient temperature and filtered through 0.2 pm nylon filters into receiving vials. The open vials were then placed into secondary containers with appropriate anti-solvents. The containers were sealed and left undisturbed at ambient conditions.
• Solids of starting material were dried at ambient or under reduced pressure at a set temperature for a specified duration.
• the BCMA-expressing multiple myeloma cells lines MM.1 S, Molp-8, H929, and
• OPM2 and the BCMA-negative acute lymphocytic leukemia cell line REH, will be expanded in RPMI medium containing L-glutamine and 5 to 10% FBS in a humidified CO2 incubator set to 37°C.
• Cells will be transferred to 96-well plates (lxlO 6 cells/mL) and cultured in the presence of increasing concentrations (0.01 nM to 3000 nM) of Form A of nirogacestat dihydrobromide or vehicle (control) in a humidified CO2 incubator set to 37°C for 5 to 24 hours. Cells will be harvested by centrifugation for 5 minutes at 400 x g and washed with an appropriate buffer.
• Cells will then be suspended in 100 pL an appropriate buffer containing an anti-human BCMA antibody and stained for 30 to 60 minutes at 4°C. Cells will be washed twice with an appropriate buffer for flow cytometry analysis. The cell viability will be determined by a commercial assay as described by the manufacturer. Expression levels of BCMA (mean fluorescence intensity) will be determined by flow cytometry.
• the BCMA-expressing multiple myeloma cells lines MM.1 S, Molp-8, H929, and
• OPM2 and the BCMA-negative acute lymphocytic leukemia cell line REH, will be expanded in RPMI medium containing L-glutamine and 5 to 10% FBS in a humidified CO2 incubator set to 37°C.
• Cells will be transferred to 96-well plates (lxlO 6 cells/mL) and cultured in the presence of increasing concentrations (0.01 nM to 3000 nM) of Form A of nirogacestat dihydrobromide or vehicle (control) in a humidified CO2 incubator set to 37°C for 5 to 24 hours.
• Cell culture media will be collected throughout and/or following a specified time and analyzed for concentration of sBCMA using a commercially available sBCMA ELISA kit according to the instructions provided by the manufacturer.
• the BCMA-expressing multiple myeloma cells lines MM.1 S, Molp-8, H929, and
• OPM2 and the BCMA-negative acute lymphocytic leukemia cell line REH, will be expanded in RPMI medium containing L-glutamine and 5 to 10% FBS in a humidified CO2 incubator set to 37°C.
• Cells will be transferred to 96-well plates (lxlO 6 cells/mL) and cultured in the presence of a fixed dose (e.g, 1 mM) of Form A of nirogacestat dihydrobromide or vehicle (control) in a humidified CO2 incubator set to 37°C.
• Targeted BCMA therapies may be added a range of concentrations to evaluate the effects of the combination on the proliferation of the multiple myeloma cells in a 3-day cellular proliferation assay (e.g. Cell-Titre Glo).
• ADCC activity of BCMA targeted antibodies will be determined using a BCMA directed IgGl monoclonal antibody in combination with Form A of nirogacestat dihydrobromide.
• ADCC activity against BCMA-expressing multiple myeloma cells lines e.g ., MM. IS, Molp-8, RPMI8226, ARH77, GA10, LP1, L363 will be measured using commercially available assays (e.g., Promega Jurkat ADCC assay) where a range of concentrations of Form A of nirogacestat dihydrobromide are combined with a range of concentrations of the BCMA targeted monoclonal antibody.
• T cells and luciferase-labeled myeloma cell lines E:T of 5:1, and serial dilutions of bispecific antibody. After 2 days of incubation, viability of cells will be assessed by OneGlo luciferase reagent (Promega).
• T-cell dependent cellular cytotoxicity (TDCC) activity of BCMA x CD3 bispecific antibody will be determined in combination with Form A of nirogacestat dihydrobromide.
• Assays will be performed by mixing CD3+ T cells and luciferase- labeled multiple myeloma cell lines (e.g, MM. IS, Molp-8, RPMI8226, ARH77, GA10, LP1, L363) using an effector-to-target ratio of 5 to 1.
• Serial dilutions of the bispecific antibody and Form A of nirogacestat dihydrobromide will result in a range of concentrations of each molecule being evaluated. After 2 days of incubation, viability of cells will be assessed using a luciferase-based assay (Promega OneGlo).
• a luciferase-based assay Promega OneGlo
• T-cell dependent cellular cytotoxicity (TDCC) activity of BCMA targeted chimeric antigen T-cell (CAR-T) cells will be determined in combination with Form A of nirogacestat dihydrobromide.
• TDCC activity against BCMA-expressing multiple myeloma cells lines e.g., MM. IS, Molp-8, RPMI8226, ARH77, GA10, LP1, L363 will be measured using custom developed TDCC assays (similar to the format described by Nazarian, A. A., et al., J. Biomol. Screen, 20:519-27 (2015)) where a range of concentrations of Form A of nirogacestat dihydrobromide will be combined with a range of BCMA targeted CAR-T cell numbers.
• T-cell activation by BCMA targeted therapies in the presence of BCMA expressing multiple myeloma cell lines (e.g., MM. IS, Molp-8, RPMI8226, ARH77, GA10, LP1, L363) will be determined in combination with Form A of nirogacestat dihydrobromide.
• Co-cultures of T-cells and multiple myeloma cell lines will be incubated with fixed concentrations of Form A of nirogacestat dihydrobromide.
• Serial dilutions of BCMA targeted therapies will be added and T-cell activation will be determined by cytokine release assays and/or flow cytometry.
• a method of treating cancer in a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the subject.
• a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the subject.
• BCMA B-cell maturation antigen
• E2 The method of El, wherein the cancer is characterized by inadequate expression of B-cell maturation antigen (BCMA).
• BCMA B-cell maturation antigen
• BCMA B-cell maturation antigen
• E5. The method of E4, wherein the hematologic cancer is multiple myeloma.
• CLL chronic lymphocytic leukemia
• DLBCL diffuse large B cell lymphoma
• FL follicular lymphoma
• BL Burkitt lymphoma
• MCL mantle cell lymphoma
• ML myelogenous leukemia
• E7 A method of treating light chain amyloidosis in a subject in need thereof comprising administering a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the subject.
• a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy to the subject.
• BCMA B-cell maturation antigen
• E10 The method of El or E7, wherein the Form A of nirogacestat dihydrobromide increases the percentage of B-cell maturation antigen (BCMA)-positive multiple myeloma cells in the subject.
• BCMA B-cell maturation antigen
• E12 The method of El or E7, wherein the Form A of nirogacestat dihydrobromide enhances the activity of B-cell maturation antigen (BCMA)-directed therapy in the subject.
• BCMA B-cell maturation antigen
• E13 The method of El or E7, wherein the Form A of nirogacestat dihydrobromide enables administration of a lower dose of the B-cell maturation antigen (BCMA)-directed therapy to the subject as compared with the amount of the BCMA- directed therapy administered alone while maintaining equal levels of efficacy.
• BCMA B-cell maturation antigen
• E14 The method of El or E7, wherein the Form A of nirogacestat dihydrobromide enables administration of a lower dose or the same dose of the B-cell maturation antigen (BCMA)-directed therapy to the subject as compared with the amount of the BCMA-directed therapy administered alone while achieving increased levels of efficacy.
• BCMA B-cell maturation antigen
• E15 The method of any one of E1-E14, wherein the subject is administered the
• Form A of nirogacestat dihydrobromide at a dose from about 20 mg to about 220 mg.
• E16 The method of any one of E1-E15, wherein the subject is administered the
• Form A of nirogacestat dihydrobromide at a dose from about 20 mg to about 220 mg once or twice daily.
• E17 The method of any one of E1-E16, wherein the subject is administered the
• Form A of nirogacestat dihydrobromide at a dose of about 50 mg once or twice daily.
• E19 The method of E16, wherein the subject is administered the Form A of nirogacestat dihydrobromide at a dose from about 20 mg to about 220 mg once or twice daily for at least one week.
• E20 The method of El 9, wherein the subject is administered the Form A of nirogacestat dihydrobromide at a dose of about 100 mg once or twice daily for at least one week.
• E21 The method of El 9, wherein the subject is administered the Form A of nirogacestat dihydrobromide at a dose of about 50 mg once or twice daily for at least one week.
• E22 The method of any one of E1-E21, wherein the subject is administered the
• E23 The method of any one of E1-E21, wherein the subject is administered the
• E24 The method of any one of E1-E21, wherein the subject is administered the
• E25 The method of any one of E1-E21, wherein the subject is administered the
• E26 The method of any one of E1-E21, wherein the subject is administered the
• E27 The method of any one of E1-E26, wherein the Form A of nirogacestat dihydrobromide is administered to the subject before, concomitantly, or subsequently to the administering of the B-cell maturation antigen (BCMA)-directed therapy to the subject.
• BCMA B-cell maturation antigen
• E28 The method of any one of E1-E27, wherein the subject is administered the combination therapy as the first line of therapy.
• E29 The method of any one of E1-E27, wherein the effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy are administered to the subject after the subject has been previously treated for the cancer or light chain amyloidosis.
• E30 The method of E29, wherein the subject has been previously treated for the cancer or light chain amyloidosis by one or more of a proteasome inhibitor, an immunomodulatory therapy, an immunotherapy, a stem cell transplant, a chemotherapy, a targeted therapy, or a B-cell maturation antigen (BCMA)-directed therapy not in combination with nirogacestat dihydrobromide to the subject.
• E31 The method of E30, wherein the immunotherapy is a monoclonal antibody.
• E32 The method of E31, wherein the monoclonal antibody is directed to CD38.
• E33 The method of any one of E1-E32, wherein the Form A of nirogacestat dihydrobromide is administered orally and the B-cell maturation antigen (BCMA)- directed therapy is administered intravenously or subcutaneously to the subject.
• BCMA B-cell maturation antigen
• E34 The method of any one of E1-E33, wherein the B-cell maturation antigen
• BCMA-directed therapy includes one or more of an allogeneic chimeric antigen receptor T cell therapy, an autologous chimeric antigen receptor T cell therapy, an immunotherapy, an antibody drug conjugate therapy, or a bispecific antibody therapy with dual specificity for BCMA and an immune-related target.
• E35 The method of E34, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least an allogeneic chimeric antigen receptor T cell therapy.
• BCMA B-cell maturation antigen
• E36 The method of E34, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least an autologous chimeric antigen receptor T cell therapy.
• BCMA B-cell maturation antigen
• E37 The method of E34, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least an immunotherapy.
• BCMA B-cell maturation antigen
• E38 The method of E34 or E37, wherein the immunotherapy is a monoclonal antibody.
• E39 The method of E34, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least an antibody drug conjugate therapy.
• BCMA B-cell maturation antigen
• E40 The method of E34, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least a bispecific antibody therapy with dual specificity for BCMA and an immune-related target.
• BCMA B-cell maturation antigen
• E41 The method of any one of E1-E40, wherein the Form A of nirogacestat dihydrobromide is administered in a tablet form.
• E42 The method of any one of E1-E41, wherein the subject is human.
• E43 Use of a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy in treating cancer in a subject in need thereof.
• BCMA B-cell maturation antigen
• E44 The use of E43, wherein the cancer is characterized by inadequate expression of B-cell maturation antigen (BCMA).
• E45 The use of E43, wherein the cancer is characterized by detectable soluble B- cell maturation antigen (BCMA) levels in a serum sample from the subject.
• BCMA detectable soluble B- cell maturation antigen
• E46 The use of E43, wherein the cancer is a hematologic cancer.
• E47 The use of E46, wherein the hematologic cancer is multiple myeloma.
• E48 The use of E43, wherein the cancer is selected from a group consisting of chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL), mantle cell lymphoma (MCL), and myelogenous leukemia (ML).
• CLL chronic lymphocytic leukemia
• DLBCL diffuse large B cell lymphoma
• FL follicular lymphoma
• BL Burkitt lymphoma
• MCL mantle cell lymphoma
• ML myelogenous leukemia
• E49 Use of a combination therapy comprising an effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy in treating light chain amyloidosis in a subject in need thereof.
• BCMA B-cell maturation antigen
• E50 The use of E43 or E49, wherein the Form A of nirogacestat dihydrobromide reduces the shedding of B-cell maturation antigen (BCMA) from the surface of a BCMA positive cell in the subject.
• BCMA B-cell maturation antigen
• E51 The use of E43 or E49, wherein the Form A of nirogacestat dihydrobromide reduces the levels of soluble B-cell maturation antigen (BCMA) in the subject.
• BCMA soluble B-cell maturation antigen
• E52 The use of E43 or E49, wherein the Form A of nirogacestat dihydrobromide increases the percentage of B-cell maturation antigen (BCMA)-positive multiple myeloma cells in the subject.
• BCMA B-cell maturation antigen
• E53 The use of E43 or E49, wherein the Form A of nirogacestat dihydrobromide increases the density of membrane bound B-cell maturation antigen (BCMA) on the surface of BCMA-positive cancer cells in the subject.
• BCMA membrane bound B-cell maturation antigen
• E54 The use of E43 or E49, wherein the Form A of nirogacestat dihydrobromide enhances the activity of the B-cell maturation antigen (BCMA)-directed therapy in the subject.
• BCMA B-cell maturation antigen
• E55 The use of E43 or E49, wherein the Form A of nirogacestat dihydrobromide enables use of a lower dose of the B-cell maturation antigen (BCMA)-directed therapy in the subject as compared with the amount of the BCMA-directed therapy administered alone while maintaining equal levels of efficacy.
• BCMA B-cell maturation antigen
• E56 The use of E43 or E49, wherein the Form A of nirogacestat dihydrobromide enables use of a lower dose or the same dose of the B-cell maturation antigen (BCMA)- directed therapy in the subject as compared with the amount of the BCMA-directed therapy administered alone while achieving increased levels of efficacy.
• BCMA B-cell maturation antigen
• E58 The use of any one of E43-E57, wherein the subject is administered the Form
• E61 The use of E58, wherein the subject is administered the Form A of nirogacestat dihydrobromide at a dose from about 20 mg to about 220 mg once or twice daily for at least one week.
• E62 The use of E61, wherein the subject is administered the Form A of nirogacestat dihydrobromide at a dose of about 100 mg once or twice daily for at least one week.
• E63 The use of E61, wherein the subject is administered the Form A of nirogacestat dihydrobromide at a dose of about 50 mg once or twice daily for at least one week.
• E66 The use of any one of E43-E63, wherein the subject is administered the Form
• E69 The use of any one of E43-E68, wherein the Form A of nirogacestat dihydrobromide is administered to the subject before, concomitantly, or subsequently to the administering of the B-cell maturation antigen (BCMA)-directed therapy to the subject.
• BCMA B-cell maturation antigen
• E70 The use of any one of E43-E69, wherein the subject is administered the combination therapy as the first line of therapy.
• E71 The use of any one of E43-E69, wherein the effective amount of Form A of nirogacestat dihydrobromide and a B-cell maturation antigen (BCMA)-directed therapy are administered to the subject after the subject has been previously treated for the cancer or light chain amyloidosis.
• BCMA B-cell maturation antigen
• E72 The use of E71, wherein the subject has been previously treated with one or more of a proteasome inhibitor, an immunomodulatory therapy, an immunotherapy, a stem cell transplant, a chemotherapy, a targeted therapy, or a B-cell maturation antigen (BCMA)-directed therapy not in combination with Form A of nirogacestat dihydrobromide.
• a proteasome inhibitor an immunomodulatory therapy
• an immunotherapy a stem cell transplant
• a chemotherapy a targeted therapy
• BCMA B-cell maturation antigen
• E73 The use of E72, wherein the immunotherapy is a monoclonal antibody.
• E74 The use of E73, wherein the monoclonal antibody is directed to CD38.
• E75 The use of any one of E43-E74, wherein the B-cell maturation antigen
• BCMA-directed therapy includes one or more of an allogeneic chimeric antigen receptor T cell therapy, an autologous chimeric antigen receptor T cell therapy, an immunotherapy, an antibody drug conjugate therapy, or a bispecific antibody therapy with dual specificity for BCMA and an immune-related target.
• E76 The use of E75, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least an allogeneic chimeric antigen receptor T cell therapy.
• BCMA B-cell maturation antigen
• E77 The use of E75, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least an autologous chimeric antigen receptor T cell therapy.
• BCMA B-cell maturation antigen
• E78 The use of E75, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least an immunotherapy.
• BCMA B-cell maturation antigen
• E79 The use of E75 or E78, wherein the immunotherapy is a monoclonal antibody.
• E80 The use of E79, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least an antibody drug conjugate therapy.
• BCMA B-cell maturation antigen
• E81 The use of E79, wherein the B-cell maturation antigen (BCMA)-directed therapy includes at least a bispecific antibody therapy with dual specificity for BCMA and an immune-related target.
• BCMA B-cell maturation antigen

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biomedical Technology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Oncology (AREA)
• Psychiatry (AREA)
• Hospice & Palliative Care (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Cell Biology (AREA)
• Hematology (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Biotechnology (AREA)
• Developmental Biology & Embryology (AREA)
• Virology (AREA)
• Zoology (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Publications (1)

Family

ID=75396879

Family Applications (1)

Country Status (17)

Cited By (9)

Citations (7)

Family Cites Families (6)

• 2021
  • 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
  • 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
  • 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
  • 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
  • 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
  • 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
  • 2021-03-12 IL IL296075A patent/IL296075A/en unknown
  • 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
  • 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
  • 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
  • 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
  • 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
  • 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
  • 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
• 2022
  • 2022-09-07 ZA ZA2022/09989A patent/ZA202209989B/en unknown
  • 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
  • 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
• 2025
  • 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending

Patent Citations (7)

Non-Patent Citations (8)

Also Published As

Similar Documents

Legal Events